definiens: means, excluding Additional Royalty Products, any AAV -directed gene therapy product which is indicated ( by way of its product label or package in sert ) for use in the Fabry Field and is Covered by any of the Fabry Program IP, Manufacturing Know -How, Serotype IP and/or Promoter Program IP licensed to Liverco hereunder ; means the program of research defined in Schedule 1 under the tit le Fabry Program as conducted prior to the Effective Date ; means the ( i ) Fabry Patent Rights and ( ii ) Program Know -How applicable to Exploitation within the Fabry Field ; means all uses and applications without restriction ; means the final written report approved by AN and written following completion of the Second Serotype Program in accordance with the applicable project plan outlined in Schedule 1, and which shall provide a complete report of the result s, findings and activities arising from the Second Serotype Program ; means the first arm ’s length commercial sale of the applicable Royalty Product in a country by Liverco or by a Sub -Licensee pursuant to a sub -license granted here under, in each case following the grant of a Marketing Approval for the applicable Royalty Product in such country ; has the meaning set out in Clause 2.4.6 means ( i ) those patent applications listed in Part A of Schedule 2 under the title ‘ First Serotype Patents ’ and all Patent Rights derived therefrom ; and ( ii ) any Future Patents filed in respect of any of the Program Know -How identified in ( ii ) of the definition of First Serotype Program IP ; means the program of research defined in Schedule 1 under the title First Serotype Program as conducted prior to the Effective Date ; means ( i ) the First Serotype Patent Rights ; and ( ii ) Program Know -How existing at the Effective Date applicable to the serotypes isolated, and/or designed and/or made under the First Serotype Program or Covered by any of the First Serotype Patent Rights, and their Exploitation ; [ * * ] means, excluding Additional Royalty Products, any gene therapy product containing or incorporating the [ * * ] any sequence variant or derivative of that gene, for the amelioration, prevention or treatment [ * * ] ; means the treatment, prevention, cure, management, diagnosis and/or control of conditions concerning or related to Factor IX, including the condition referred to as ‘ Haemophilia B ’, and associated symptoms ; has the meaning set out in Clause 2.4.2 ; 9 Certain confidential information contained in this document, marked by [ * * ], has been omitted because the information ( i ) is not material and ( ii ) would likely cause competitive harm to the Company if publicly disclosed